Clinical and Economic Validation of the ISGPS Definition of PPAP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective validation study aims to investigate the incidence of PPAP after pancreaticoduodenectomy (PD) by applying the ISGPS definition and grading system, to demonstrate its clinical impact by examining associated postoperative outcomes, and to validate its applicability through an economic assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Operative Acute Pancreatitis After Pancreaticoduodenectomy

NCT04917172

Acute Pancreatitis Pancreatic Fistula Postoperative Complications

COMPLETED

Prediction of PEP Based on the Appearance of the Major Duodenal Papilla

NCT05800626

Post-ERCP Acute Pancreatitis

RECRUITING

Late Phase Acute Pancreatitis: a Tailored Step-up Approach

NCT04870268

Acute Pancreatitis

COMPLETED

Pancreaticoduodenectomies With Complete Arterial Coverage by Retromesenteric Omentoplasty

NCT05992857

Pancreatectomy Complication of Surgical Procedure

RECRUITING NA

Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy

NCT00830778

Tumors

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted at approximately 37 investigative sites in Europe, Asia, Oceania, and the United States. Only high volume centers for Pancreatic Surgery will be included in the study. All patients scheduled to receive elective pancreaticoduodenectomy (PD Kausch-Whipple or Longmire-Traverso) for all type of pancreatic disease (benign, malignant, or premalignant) will be enrolled. The study duration per subject will be up to 30 days after surgery or all the in-hospital lengths of stay. Preoperative care will follow institutional standards, according to each center involved. Surgical resection and reconstruction will be carried out according to the techniques adopted by each participating center. Both patients undergoing open and minimally invasive surgery can be considered eligible. Postoperative management will follow the institutional standards of each center. Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days (POD) 1 and 2.Serum C-reactive protein (CRP) will be measured according to each institutional policy and reported once assessed from POD 1 to 3. Drain fluid amylase, or lipase activity will be checked according to the Institutional standards of each involved, and the values will be retrieved whether assessed from POD 1 to five. Radiological imaging will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious for abdominal complications.The severity of complications will be assessed according to the Clavien-Dindo (CD) classification system 32 . Readmission will be defined as a new hospital admission after discharge within 30 days from index surgery. Length of hospital stay is calculated from the day of surgery to discharge. Preoperative, intra-operative, and postoperative data will be recorded prospectively.

The estimated study duration will be 15 months. Time for data analysis must be considered negligible. Patients' follow-up will last 30 days after surgery to catch any additional morbidity even after discharge from the hospital.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Acute Pancreatitis Pancreaticoduodenectomy Postoperative Pancreatic Fistula Postoperative Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study population

Subgroups based on the ISGPS diagnostic criteria and the grading system of PPAP:

1. Without PPAP or POH: Patients without POH nor imaging consistent with AP.
2. POH: sustained postoperative serum hyperamylasemia neither clinically relevant nor consistent imaging
3. PPAP: requiring the fulfilment of three criteria:

* POH: sustained serum hyperamylasemia greater than the institutional upper limit of normal persisting on postoperative days 1 and 2;
* macroscopic radiologic features of AP
* clinically relevant complications. PPAP severity will be classified into grades B and C, with progressive clinical deterioration.

PPAP diagnosis

Intervention Type DIAGNOSTIC_TEST

Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.

A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PPAP diagnosis

Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.

A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled for elective PD;
* Male and females ≥ 18 years;
* Upfront or after neoadjuvant therapy surgery is allowed;
* The ability of the subject to understand the character and individual consequences of the clinical trial;
* Written informed consent.

Exclusion Criteria

* Patients undergoing emergency surgery;
* Informed consent withdrawal;
* Inability to perform the resection for any reason;
* Total or distal pancreatectomy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No